Orbis Medicines: Funding, Investors & Team (Sep 2026)
Orbis Medicines utilizes a unique combination of macrocyclic chemistry and computational technology to discover oral macrocycle drugs. Their platform produces optimized macrocycle candidates, called nCycles, with improved oral bioavailability. The company is currently developing nCycle candidates targeting established therapeutic targets typically addressed by injectable blockbuster biologic drugs.
Orbis Medicines has raised $93.2M across 1 funding round on record, the most recent a Series A of $93.2M announced in Jan 2025.
That round is above the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Orbis Medicines Company Profile and Key Stats
Latest funding round on record: Jan 2025.
Orbis Medicines Funding Rounds
Orbis Medicines Founders and Leadership Team
No contact details are on record for this team yet.
Orbis Medicines Funding Compared to Other Health Care Startups
Orbis Medicines' latest round of $93.2M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Orbis Medicines in Health Care and Copenhagen
Companies Similar to Orbis Medicines
DARERL develops a software platform for early-stage testing and development of medical devices and wearables.…
The Droplet IV administers a flush to each IV set exactly when the medication ends, guaranteeing that…
Dawn Health specializes in creating digital health solutions, with a focus on Software as a Medical Device…
Cercare Medical creates software to assist in the assessment of acute stroke, enabling quick evaluation of…
Scandinavian Biolabs is a Danish brand that is dedicated to creating effective solutions for hair growth. Our…
Cessatech is a company in the pharmaceutical industry that focuses on creating and bringing to market new…
CS MEDICA A/S is a medtech company that works in research, development, manufacturing, and commercialization,…
At Brain+, we value your brain as your most valuable possession. Your brain should receive equal or greater…
Woba is a software-as-a-service (SaaS) that strives to facilitate a work environment with reduced stress and…
CathVision helps guide ablation therapy of cardiac arrhythmia with novel hardware, software and data science.
Levvel Health is a Danish Healthtech company founded in March 2020 in response to the COVID-19 pandemic. We…
Sumondo is a digital health care company, our product is stress management using wearable devices.
Orbis Medicines Funding FAQs
What does Orbis Medicines do?
Orbis Medicines utilizes a unique combination of macrocyclic chemistry and computational technology to discover oral macrocycle drugs. Their platform produces optimized macrocycle candidates, called nCycles, with improved oral bioavailability. The company is currently developing nCycle candidates targeting established therapeutic targets typically addressed by injectable blockbuster biologic drugs.
How much funding has Orbis Medicines raised?
Orbis Medicines has raised $93.2M across 1 round on record. The most recent is a Series A of $93.2M announced in Jan 2025.
When did Orbis Medicines last raise funding?
Orbis Medicines' most recent funding round on record is a Series A of $93.2M, announced in Jan 2025.
Who founded Orbis Medicines?
FundedIQ lists Sevan Habeshian (Founder) at Orbis Medicines.
Where is Orbis Medicines headquartered?
Orbis Medicines is based in Copenhagen, Hovedstaden, Denmark.
How many employees does Orbis Medicines have?
Orbis Medicines is in the 11-50 employee band.
How does Orbis Medicines' funding compare to other Health Care startups?
Orbis Medicines' latest round of $93.2M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Orbis Medicines Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Orbis Medicines is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.